A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824001319 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129658130989056 |
|---|---|
| author | G.V. Long R. Gutzmer A. Haydon E. Muñoz Couselo C. Lebbé M. Carlino W. Chow F. Couture P. Lau F. Spagnolo A.J. Alves Wainstein D. Palmieri C. Rojas García G. de Velasco Oria de Rueda I. Mehmi D. Patel A. Shaikh N.R. Chowdhury S. Bathena S. Suryawanshi P. Rutkowski |
| author_facet | G.V. Long R. Gutzmer A. Haydon E. Muñoz Couselo C. Lebbé M. Carlino W. Chow F. Couture P. Lau F. Spagnolo A.J. Alves Wainstein D. Palmieri C. Rojas García G. de Velasco Oria de Rueda I. Mehmi D. Patel A. Shaikh N.R. Chowdhury S. Bathena S. Suryawanshi P. Rutkowski |
| author_sort | G.V. Long |
| collection | DOAJ |
| format | Article |
| id | doaj-art-cc12cef4e36d44d48a9f5a80b94ccceb |
| institution | OA Journals |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-cc12cef4e36d44d48a9f5a80b94ccceb2025-08-20T02:32:54ZengElsevierEJC Skin Cancer2772-61182024-01-01210014310.1016/j.ejcskn.2024.100143A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)G.V. Long0R. Gutzmer1A. Haydon2E. Muñoz Couselo3C. Lebbé4M. Carlino5W. Chow6F. Couture7P. Lau8F. Spagnolo9A.J. Alves Wainstein10D. Palmieri11C. Rojas García12G. de Velasco Oria de Rueda13I. Mehmi14D. Patel15A. Shaikh16N.R. Chowdhury17S. Bathena18S. Suryawanshi19P. Rutkowski20Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AustraliaJohannes Wesling Medical Center Minden, Minden, GermanyThe Alfred Hospital, Melbourne, AustraliaHospital Universitario Vall d'Hebron, Barcelona, SpainHôpital Saint-Louis, Paris, FranceWestmead Hospital, Sydney, AustraliaUC Irvine Health, Irvine, CA, United States of AmericaHôpital de l'Enfant Jésus, Quebec City, CanadaSir Charles Gairdner Hospital, Nedlands, AustraliaIRCCS Ospedale Policlinico San Martino, Genova, ItalyOncologia de Preciso e Personalizada, Santa Efigênia, Belo Horizonte, BrazilRiverina Cancer Care Centre, Wagga Wagga, AustraliaBradford Hill Centro de Investigación Clínica, Recoleta, ChileHospital Universitario 12 de Octubre, Madrid, SpainThe Angeles Clinic and Research Institute, Los Angeles, CA, United States of AmericaBristol Myers Squibb, Princeton, NJ, United States of AmericaBristol Myers Squibb, Princeton, NJ, United States of AmericaBristol Myers Squibb, Princeton, NJ, United States of AmericaBristol Myers Squibb, Princeton, NJ, United States of AmericaBristol Myers Squibb, Princeton, NJ, United States of AmericaMaria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Polandhttp://www.sciencedirect.com/science/article/pii/S2772611824001319 |
| spellingShingle | G.V. Long R. Gutzmer A. Haydon E. Muñoz Couselo C. Lebbé M. Carlino W. Chow F. Couture P. Lau F. Spagnolo A.J. Alves Wainstein D. Palmieri C. Rojas García G. de Velasco Oria de Rueda I. Mehmi D. Patel A. Shaikh N.R. Chowdhury S. Bathena S. Suryawanshi P. Rutkowski A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) EJC Skin Cancer |
| title | A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) |
| title_full | A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) |
| title_fullStr | A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) |
| title_full_unstemmed | A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) |
| title_short | A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127) |
| title_sort | phase 3 study of the efficacy safety and pharmacokinetics profile of subcutaneous vs intravenous nivolumab relatlimab fixed dose combination in previously untreated metastatic or unresectable melanoma relativity 127 |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824001319 |
| work_keys_str_mv | AT gvlong aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT rgutzmer aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ahaydon aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT emunozcouselo aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT clebbe aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT mcarlino aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT wchow aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT fcouture aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT plau aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT fspagnolo aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ajalveswainstein aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT dpalmieri aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT crojasgarcia aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT gdevelascooriaderueda aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT imehmi aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT dpatel aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ashaikh aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT nrchowdhury aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT sbathena aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ssuryawanshi aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT prutkowski aphase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT gvlong phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT rgutzmer phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ahaydon phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT emunozcouselo phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT clebbe phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT mcarlino phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT wchow phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT fcouture phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT plau phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT fspagnolo phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ajalveswainstein phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT dpalmieri phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT crojasgarcia phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT gdevelascooriaderueda phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT imehmi phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT dpatel phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ashaikh phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT nrchowdhury phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT sbathena phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT ssuryawanshi phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 AT prutkowski phase3studyoftheefficacysafetyandpharmacokineticsprofileofsubcutaneousvsintravenousnivolumabrelatlimabfixeddosecombinationinpreviouslyuntreatedmetastaticorunresectablemelanomarelativity127 |